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SUMMARY 
Background: Drug resistant tuberculosis (TB) which is a state when Mycobaterium tuberculosis (MTB) organisms 
are resistant to antimicrobial agents at the levels attainable in blood and tissue pose a serious threat to TB control 
programs. Limited information exists on the exact prevalence of resistance to anti-tuberculosis drugs in 
populations with high rates of tuberculosis and HIV co-infection such as those in Nairobi, Kenya. 
Setting: A cross sectional study was conducted among new and previously treated consecutive sputum smear 
positive pulmonary tuberculosis (PTB)   patients of 14 years and older at 16 diagnostic and treatment facilities in 
Nairobi, Kenya, between February and August 2010.  
Objective: To determine the magnitude of  drug resistance to first line antituberculosis drugs among MTB  isolates 
obtained from a study addressing  the diagnosis and epidemiology of drug resistant tuberculosis in Nairobi, Kenya. 
Methods: Sputum samples from patients with bacteriologically confirmed PTB on microscopy were cultured on 
Lowenstein Jensen (LJ) media. Participants were offered diagnostic testing and counselling for HIV testing. Strains 
of MTB complex from Lowenstein Jensen (LJ) slopes were subjected to drug susceptibility testing (DST) to 
isoniazid (H), rifampicin (R), streptomycin (S), and ethambutol (E) using the proportional method on the 
Mycobacterium Growth Indicator Tube (MGIT) conventional method.   
Results: A total of 595 TB patients had their MTB strains  DST done. Of the 568 (95.4%) patients who had valid 
results for analysis, 369 were new and 199 previously treated. About eighty five percent and seventy seven percent 
of the strains from new patients and previously treated patients were fully sensitive to all the drugs tested 
respectively. Any resistance to isoniazid, streptomycin, ethambutol and rifampicin was 10.3%, 4.3%, 5.1% and 
0.81% respectively among new patients. Among previously treated patients any resistance to isoniazid, 
streptomycin, ethambutol and rifampicin was 18.1%, 10.5%, 7.03% and 9.04% respectively. The prevalence of 
MDR TB defined as resistant to at least both isoniazid and rifampicin was 0.54% and 8.54% among new and 
previously treated patients respectively.   
Conclusion:  The study found  high levels of drug resistant TB in Nairobi compared to other previous studies done 
in the  country. MDR TB in Kenya is now a reality and the situation in Nairobi being the  largest cosmopolitant city 
is worrying. The upword trend of MDR TB in Nairobi is course of concern. This calls for urgent concerted efforts 
to address the problem especially the strenghthening of the implementation of the  comprehensive framework of  




Drug resistance of Mycobacterium tuberculosis which is 
a state when Mycobaterium tuberculosis organisms are 
resistant to antimicrobial agents at the levels attainable 
in blood and tissue was recognized soon after the 
introduction of anti-tuberculosis drugs in late 1940s1,2. 
The re-emergence of drug resistant TB especially 
multidrug resistant TB (MDR TB) poses a serious threat 
to TB control programs all over the world3. Resistance to 








mutations,  non-adherence to drugs and inadequate 
tuberculosis treatment.  Primary resistance is the 
presence of drug resistant MTB in a patient with no or 
less than one month of previous antituberculosis drug 
therapy. On the other hand acquired resistance the 
patient has received at least one month of 
antituberculosis drugs in the past.  Primary resistance 
reflects the transmission of TB over the years  while 
acquired resistance is a good measure of TB programme 
perfomance since it includes relapse cases, treatment 
failures and defaulters4.  
Early detection of TB drug resistance allows prompt 
initiation of the appropriate treatment in patients and 
surveillance of drug resistance. It is one of the key 
priorities of the TB control program. However   limited 
information exists on the exact prevalence of resistance 
to anti-tuberculosis drugs in populations with high rates 
of tuberculosis and HIV co-infection such as those in 
Nairobi, Kenya.  Data from routine drug sensitivity 
testing from the National reference laboratory (CRL) 
shows resistance to rifampicin and isoniazid to be 10% 
and 20% respectively for previously treated pulmonary 
tuberculosis patients5. In 2007 alone 118 Multidrug 
resistance TB cases were reported in Kenya from the 
routine MDR-TB surveillance. This was based on only 
1,500 (14% of all retreatment cases) samples analyzed at 
the central reference laboratory6.  As of  April 2009 one  
case of XDR-TB had been reported in the Western part 
of Kenya in Busia7. The high rates of drug resistance TB 
currently being reported in Kenya is alarming.  In 2006, 
WHO estimated a total of 400,000 Multi-drug resistant 
TB (MDR-TB) to have occurred in the world of which 
7,000 MDR-TB cases were reported from African 
countries8. In most areas of the world where TB is 
common, reliable pretreatment drug susceptability 
results are not available. However epidemiological 
studies have shown that most previously treated patients 
with drug resistance initially had primary drug 
resistance9. Mycobacterium tuberculosis strains resistant 
to anti-TB drugs can  be transmitted the same way MTB 
strains susceptible to anti-TB drugs are transmitted. 
Evidence that MDR TB strains have the potential for 
transmission has been reported in a series of outbreaks in 
hospitals10, 11 amongst health care workers12,13 and in 
prisons14,. 
Resistance to any anti-TB drug is predictable if the drug 
is used alone. A similar resistance is expected if only 
one drug is in a regimen were effective because of 
preexisting resistance to other drugs in the regimen15. 
Rifampicin needs special protection because it is the key 
sterilizing drug in short course treatment of 
tuberculosis16. 
 Among patients with drug resistance TB, additional 
drug resistance may develop if a regimen with multiple 
drugs is prescribed that includes drugs against which 
primary resistance is present. Such a regimen may be 
equivalent to a single drug therapy. In Vietnam it was 
shown that primary resistance was a strong factor for 
failure and relapse and for acquiring further resistance17. 
MDR-TB is a severe form of drug resistance and is on 
the increase in many countries of the world . Most 
childhood contacts of adults with MDR-TB are likely to 
be infected with MDR-TB. Contact tracing is therefore 
important in identifying children at risk and also know 
the susceptibility patterns of the index case in order to 
choose a proper treatment regimen for the contacts18, 19. 
TheWorld Health Organization has proposed in the 
global plan to stop TB 2006-2015 several components 
including addressing TB/HIV and MDR-TB20. Human 
Immunodeficiency Virus (HIV) infection curtails the 
effects of TB control programme by lowering the life 
expectancy of those receiving TB treatment.  The “direct 
costs” of diagnosis and treatment are significant for poor 
families, but the greatest economic loss occurs as a result 
of “indirect” costs, such as loss of employment, travel to 
health facilities, sale of assets to pay for treatment 
related costs, and in particular, lost productivity from 
illness and premature death21. The greatest economic 
benefits of the global plan to stop TB are greatest in 
African countries especially those with high levels of 
HIV22.  
Directly Observed treatment short course (DOTs) 
strategy can rapidly reduce the transmission and 
incidence of both drug susceptible and drug resistance 
TB.  However, standardized or individualized treatment 
regimen may be required based on the Drug Sensitivity 
Testing (DST) to reduce mortality rates due to MDR-
TB23. Primary drug resistance is a strong risk factor for 
failure and relapse for acquiring further resistance. In 
Vietnam it was shown that 17 out of 40 (43%) of the 
failure patients enrolled for retreatment had primary 
MDR-TB and 15 out of 25 (65%)  of the patients 
enrolled for retreatment who did not have primary 
MDR-TB had acquired MDR-TB24. The treatment of 
MDR-TB is expensive and takes long time though most 








appropriate regimen. Second line drug also have many 
side effects25. Aminoquinolones are among the second 
line anti-TB drugs and the widespread use of 
aminoquinolones such as ciprofloxacin and ofloxacin for 
other infections may render them significantly less 
effective alternative therapy for MDR-TB26. 
Extensively drug resistance TB (XDR-TB) also defined 
as MDR-TB with further resistance to at least three of 
the six classes of second line drugs anti-TB drugs is also 
becoming a threat to public health worldwide. Of the 
221 patients who had MDR-TB and were studied in 
South Africa in September 2006, 53 cases were 
identified with XDR-TB. This represented almost one-
sixth of all the known XDR-TB cases in the whole 
world27.  
Materials and Methods 
Setting: The study was conducted in Nairobi, the capital 
city of Kenya. The population of Nairobi is steadly 
growing due to rural-urban migration and immigration 
from unstable countries e.g  Somalia and Sudan. A 
significant proportion of the residents of Nairobi belong 
to the middle or low social economic class with high 
population densities in certain areas. The total area of 
Nairobi is  696 sq km with about 60% of the people 
living in less than 5% of this area in  overcrowded 
informal settlements in the form of shelters.  Nairobi has 
the highest TB case load compared to other regions in 
Kenya. In 2007 there were  18,902 (684/100,000) of all 
forms of TB cases and 6,634  (242/100,000 ) of the new 
smear positive TB cases. 
There are 8 health districts in Nairobi divided based on 
the geographical location and population sizes for  
operational issues. All the 8 districts  were selected for 
the study. The study was cross sectional and to get the 
number of patients per district  the required sample size 
was  divided proportionately to the 8 districts depending 
on the number of smear positive TB patients diagnosed 
by each district  in 2007. A list of all public diagnostic 
centers in each district  was compiled and ranked 
according the number of new smear positive TB cases 
diagnosed in 2007. The intake period was between 
February and August 2010 i.e at 6 months maximum 
duration in order to minimise operational costs. The 
diagnostic facility in each of the health districts with the 
highest number of patients diagnosed in a quarter of a 
year was selected. This approach was used because the 
facilities selected would capture most of the TB patients 
in that particular health district and reach the required 
sample size within the intake period. If the calculated 
number of patients in the first facility was not adequate 
for the particular district, then additional patients were 
recruited from the next nearest dignostic facility within 
the district. Consecutive eligible patients (both new and 
previously treated) diagnosed and/or registered for 
treatment at each of the selected diagnostic sites  during 
the intake period and   gave consent were enrolled for 
the study .  
Specimen  collection and transport 
At the peripheral laboratory, the standard Acid –fast 
(AFB) direct smear microscopy using Zeihl-Neelsen 
(ZN) staining was done on the initial sputum to confirm 
TB diagnosis of suspected patients.  A second sputum 
specimen was then collected before start of treatment 
and then transported to the Central reference Laboratory 
(CRL) on the same day for culture. The central reference 
laboratory is located within the Centre for Respiratory 
Diseases Research, Kenya Medical Research Institute 
(CRDR- KEMRI)  at Kenyatta National Hospital.  
Culture of  M. Tuberculosis and drug susceptability 
testing. 
Central reference laboratory (CRL) is the only public 
laboratory which does sputum culture and drug 
susceptability testing for M. tuberculosis. Primary 
culture of M. tuberculosis was perfomed on egg based 
solid culture media,  Lowenstein-Jensen (LJ). Sputum 
specimens were first decontaminated using 4% sodium 
hydroxide to eliminate the associated  commensal flora. 
The decontaminated sputum specimens were then 
homogenized  by vortexing and then centrifuged for 15 
minutes at 300 revolutions per minute (rpm). The 
sediment obtained after centrifuging was inoculated 
directly to the LJ culture media slopes and incubated at 
370C. The slopes were examined weekly for any visible 
growth. A positive culture of M. tuberculosis confirmed 
the diagnosis of active TB disease.  Strains of MTB 
complex from Lowenstein Jensen (LJ) slopes were 
subjected to drug susceptibility testing (DST) to 
Isoniazid (INH), rifampicin (RIF), streptomycin (SM), 
and ethambutol (EMB) using the Mycobacterium 
Growth Indicator Tube (MGIT) method.   
A loopful of the colonies was harvested from the LJ 
slants, suspended in 1ml sterile saline and vortexes to 
break the large clumps. The suspension was adjusted to a 








The drug containing and drug-free growth control MGIT 
tubes were inoculated with the standardized 0.5 
McFarland inoculums of the M. tuberculosis isolate and 
entered into the MGIT960 automated machine in a 
special rack-carrier with a printed barcode; this is read 
by the machine when entering the tubes to identify the 
test and apply the adequate algorithm for susceptibility 
or resistance interpretation. All readings were performed 
inside the machine and the results were printed as 
susceptible or resistant for each drug tested.  
Results  
A total of 691 pulmonary tuberculosis patients were 
enrolled for study  in  the 8 health districts of whom  438 
were new smear positive PTB patients  and 253 were 
previously treated smear positive patients.  
Of the 690 patients for whom data was available, 446 
Table 1: Patterns of resistance to first line anti-tuberculosis drug  in Nairobi, 2010 
Newly diagnosed patients Previously treated patients Total 
Item Number % 95% CI Number % 95% CI  N % 95%CI 
Number of DST 369 100   199 100   568   
Sensitive to all  312 84.6  80.6-87.9 153 76.9  70.7-82.3 465 81.9 78.6-84.9 
Any Resistance   
Isoniazid (H) 38 10.3  7.5-13.7 36 18.1  13.2-23.8 74 13.2 10.4-15.9 
Rifampicin (R,) 3 0.81 0.19-2.10 18 9.04 5.59-13.5 21 3.7 3.24-5.57 
Ethambutol (E) 19 5.1  3.19-7.72 14 7.02 4.02-11.1 33 5.8 4.08-7.94 
Streptomycin (S) 16 4.3  2.56-6.74 21 10.5 6.8-15.3 37 6.5 4.68-8.74 
Monoresistance TB   
Isoniazid (H) 24 6.50 4.28-9.33 13 6.5 3.64-10.5 37 6.5 4.68-8.74 
Rifampicin (R,) 1 0.27 0.01-1.28 1 0.50 0.02-2.36 2 0.35 0.05-1.12 
Ethambutol (E) 10 2.71 1.36-4.71 5 2.51 0.9-5.3 15 2.6 1.52-4.18 
Streptomycin (S) 8 2.17 0.99-4.0 4 2.0 0.6-4.66 12 2.1 1.13-3.53 
Multidrug resistance TB (MDR TB)   
H+R 0 0  0 3 1.51 0.36-3.92 3 0.5 0.13-1.39 
H+R+E 1 0.27  0.01-1.28 2 1.0 0.15-3.17 3 0.5 0.13-1.39 
H+R+S 0 0  0 6 3.0 1.19-6.04 6 1.05 0.42-2.14 
H+R+E+S 1 0.27 0.01-1.28 6 3.0 1.19-6.04 7 1.2 0.53-2.38 
Total MDR TB 2 0.54 
0.083-
1.72 17 8.54 5.19-12.9 19 
3.35 2.06-5.04 
Other resistance Patterns   
H+E 5 1.36  0.48-2.91 1 0.5  0.02-2.36 6 1.05 0.42-2.14 
H+S 5 1.36  0.48-2.91 5 2.51 0.9-5.3 10 1.76 0.88-307 
H+E+S 2 0.54  0.83-1.72 0 0  0 2 0.35 0.054-1.12 
R+E 0 0  0   0  0 0   
E+S 0 0  0 0 0  0 0   
R+S 0 0  0 0 0  0 0   








(64.7%) were males and 244 (35.3%) were females with 
a mean age of 31.3 years, median and mode of 30 years. 
The minimum age was 14 years and maximum age 84 
years. A total of 485 patients (311 males and 174  
females) were tested for HIV of whom 155 (32%) tested 
positive while 330 (68%) tested negative for HIV. 
Fourty one percent of the female patients tested positive 
while only 27% of the males tested positive for HIV. 
Culture was positive in sputum from 595 (86.1%) 
patients. Of the 595 strains subjected to drug 
suaceptabilty testing, 568  cultures of M. tuberculosis 
were available for analysis of whom 369 were new cases  
and 199 previously treated. Strains of 312 (84.5%) of 
new patients and 153(76.9%) of previously treated 
patients were fully sensitive to all antituberculosis drugs 
tested. Any  resitance pattern among new patients was as 
follows; isoniazid 38 (10.3%). ethambutol 19 (5.1%), 
streptomycin 16 (4.3%) and rifampicin 3 (0.81%). 
Among  previously treated patients the resistance pattern 
was isoniazid 34 (18.1%), streptomycin 21 (10.5%)  
ethambutol 14 isolates (7.02%) and rifampicin 18 
(9.04%). Two (0.54%) and 17 (8.54%) strains from new 
and previosely treated patients  respectively were 
multidrug resistant TB (MDR TB) defined as resistant to 
at least both isoniazid and rifampicin (Table 1). 
Discussions: 
Drug resistance in tuberculosis is a matter of great 
concern for TB control programs since resistant 
Mycobacterium tuberculosis strains could spread around 
the world. The increasing prevalence of TB and HIV 
infection is also worrying.  Resistance to at least one 
anti-tuberculosis drug in the world ranges from 0% in 
two Western European countries i.e. United Kingdom 
and Iceland to 56.3% in Baku and Azerbaijan. Among 
previously treated patients’ resistance to at least one 
anti-tuberculosis drug ranges from 0% in three European 
countries to 86% in TashKent and up to 60% for MDR-
TB with 4012 MDR-TB cases reported all over the 
world between 2002-2006, 301 (7%) being XDR-TB 
cases28. As of January 2008 a total of 58 countries 
worldwide including Kenya had reported to the World 
Health Organization (WHO) at least one case of XDR-
TB.  WHO recommends that in order to prevent 
emergency of XDR-TB, countries should strengthen 
laboratory diagnostic services to ensure rapid and 
accurate DST and also increase disease surveillance 
efforts to asses epidemiological trends29.  
Initial drug resistance surveys performed in Kenya in 
1964, 1974 and 1984, indicated that Initial resistance 
ranged from 7.1% to 8.9% for isoniazid (H), from 0.5% 
to 1.4% for streptomycin and from 1.3% to 1.4% for 
both H and S combined while acquired resistance ranged 
between 16% and 17% for H and between 2% and 16% 
for both H and S. There was no resistance to 
rifampicin30. A countrywide survey carried out by Githui 
et al. in Kenya in 1994, showed that among patients with 
no previous exposure, 6.3% had a strain resistant to 
either isoniazid (5.3%) or both isoniazid and 
streptomycin (1%) while in those with  previous 
exposure 37% of the patients had a strain resistant to 
either isoniazid (30.4%) or both isoniazid and 
streptomycin (6.5%). However no resistance was 
recorded in rifampicin and ethambutol unlike in the 
present study where resistance was recorded in both new 
and previously treated patients31. In another study 
carried out in Nairobi between September 1999 and 
October 2001, MDR TB was documented in 17 (11.4%) 
out of 209 isolates32. Recurrent TB has been identified as 
the most important risk factor for resistance to isoniazid, 
rifampicin or both in a study carried out by Zhiyuan et al 
in New Jersey, USA33. Irregular treatment which is also 
a common problem in big cities like Nairobi due to 
frequent movements has been associated with MDR-
TB34. High prevalence of drug resistance in HIV 
infected TB patients has been reported. Studies in 
Lativia showed that any resistance and MDR-TB were 
significantly associated with HIV infection.  Taylor et 
al., found out in a study in Texas that TB patients with 
HIV were more likely to have rifampicin resistance and 
less likely to have isoniazid resistance35. However a 
study done in Puna, Maharashltra India on anti-TB drug 
resistance showed that prevalence of drug resistant 
isolates among HIV seropositive patients was similar to 
that of HIV seronegative TB patients indicating that HIV 
infection may not be associated with drug resistant TB36. 
Tuberculosis infections in high incidence countries have 
been shown to be recently transmitted and failure to 
contain MDR TB and XDR TB reflects inability to 
diagnose the problem early to prevent transmission of 
the same while continuing to prescribe an ineffective 
regimen37. Once MDR TB has developed, further 
progression to pre-XDR and XDR is only a question of 
time and will take place over few months or even years.  
The patient remains infectious and transmission of MDR 
TB and XDR TB continues particularly in areas with 








emergence of  MDR TB in Nairobi is therefore a course 
of concern and calls for urgent attention to address the 
problem of drug resistant TB.  Concerted efforts are 
therefore required to prevent drug resistance and 
effectively treat patients with MDR-TB as a crucial 
protection of public health and TB control. The DOTS 
strategy developed in 1970s and 1980s can prevent 
MDR TB from becoming a serious problem in a 
population and also reduce MDR TB once it has 
occurred.  We  call for strenghthened   efforts  on the 
implementation of the  comprehensive framework of 
DOTS-Plus strategy  that add components for MDR-TB 
diagnosis, management and treatment integrated within 
the DOTS programs. 
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